MiNK Q1 cash $9.5M, net loss $2.7M; initiates randomized Phase 2 for agenT-797 in ARDS

MiNK Therapeutics, Inc.

Cash $9.5M at Mar 31 (down from $13.4M at Dec 31); repaid $5.2M Agenus convertible note.
Net loss $2.7M ($0.57/sh) vs $2.8M ($0.70/sh) year ago; raised $3.0M via ATM in Q1.
Initiated randomized Phase 2 trial of agenT-797 in severe acute lung injury/ARDS; data expected H2 2026.
Non-dilutive C-Further collaboration provides up to $1.1M for PRAME-targeted iNKT therapy in pediatric cancers.
Upcoming ATS presentation May 20 on agenT-797 for coccidioides infection; NIH-funded GvHD program ongoing.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.